Hm Payson & CO Bluebird Bio, Inc. Transaction History

Hm Payson & CO

$5.81 Billion
Q3 2024

A detailed history of Hm Payson & CO transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Hm Payson & CO holds 5,000 shares of BLUE stock, worth $1,750. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,000

Previous 5,000 -0.0%

Holding current value

$1,750

Previous $4,000 50.0%

% of portfolio

0.0%

Previous 0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.85 - $1.26 $3,400 - $5,040	4,000 Added 400.0%	5,000 $4,000
Q4 2023 Feb 13, 2024	SELL	$1.32 - $4.83 $792 - $2,898	-600 Reduced 37.5%	1,000 $1,000
Q3 2023 Nov 06, 2023	BUY	$3.02 - $4.05 $1,812 - $2,430	600 Added 60.0%	1,600 $4,000
Q3 2021 Nov 30, 2021	BUY	$11.24 - $21.0 $5,620 - $10,500	500 Added 100.0%	1,000 $19,000
Q2 2021 Aug 17, 2021	BUY	$18.04 - $22.09 $9,020 - $11,045	500 New	500 $16,000
Q4 2020 Mar 10, 2021	SELL	$27.5 - $37.92 $9,185 - $12,665	-334 Closed	0 $0
Q3 2020 Dec 21, 2020	BUY	$34.44 - $43.75 $11,502 - $14,612	334 New	334 $18,000

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

News

Stay updated on Hm Payson & CO with notifications on news.

Account